Rongsha Chen, Ke Li, Yinying Wang, Liyun Song, Ruohua Wang, Wenhui Fan, Ninghui Zhao, Wei Zou, Zhongshan Yang, Jinyuan Yan
{"title":"Valeric acid reduction by chitosan oligosaccharide induces autophagy in a Parkinson's disease mouse model.","authors":"Rongsha Chen, Ke Li, Yinying Wang, Liyun Song, Ruohua Wang, Wenhui Fan, Ninghui Zhao, Wei Zou, Zhongshan Yang, Jinyuan Yan","doi":"10.1080/1061186X.2024.2315468","DOIUrl":null,"url":null,"abstract":"<p><p>Parkinson's disease (PD) is a central nervous system disease with the highest disability and mortality rate worldwide, and it is caused by a variety of factors. The most common medications for PD have side effects with limited therapeutic outcomes. Many studies have reported that chitosan oligosaccharide (COS) crossed blood-brain barrier to achieve a neuroprotective effect in PD. However, the role of COS in PD remains unclear. The present study demonstrated that COS increased dopaminergic neurons in the substantia nigra (SN) and ameliorated dyskinesia in a PD mouse model. Moreover, COS reduced gut microbial diversity and faecal short-chain fatty acids. Valeric acid supplementation enhanced the inflammatory response in the colon and SN, and it reversed COS - suppressed dopamine neurons damage. Autophagy was involved in COS modulating inflammation through valeric acid. These results suggest that COS reduces bacterial metabolites - valeric acid, which diminishes inflammation <i>via</i> activating autophagy, ultimately alleviating PD.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Targeting","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1061186X.2024.2315468","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Parkinson's disease (PD) is a central nervous system disease with the highest disability and mortality rate worldwide, and it is caused by a variety of factors. The most common medications for PD have side effects with limited therapeutic outcomes. Many studies have reported that chitosan oligosaccharide (COS) crossed blood-brain barrier to achieve a neuroprotective effect in PD. However, the role of COS in PD remains unclear. The present study demonstrated that COS increased dopaminergic neurons in the substantia nigra (SN) and ameliorated dyskinesia in a PD mouse model. Moreover, COS reduced gut microbial diversity and faecal short-chain fatty acids. Valeric acid supplementation enhanced the inflammatory response in the colon and SN, and it reversed COS - suppressed dopamine neurons damage. Autophagy was involved in COS modulating inflammation through valeric acid. These results suggest that COS reduces bacterial metabolites - valeric acid, which diminishes inflammation via activating autophagy, ultimately alleviating PD.
帕金森病(PD)是一种中枢神经系统疾病,是全球致残率和死亡率最高的疾病,其病因多种多样。治疗帕金森病的最常见药物都有副作用,且治疗效果有限。许多研究报告称,壳聚糖低聚糖(COS)可穿过血脑屏障,对帕金森病具有神经保护作用。然而,COS在帕金森病中的作用仍不明确。本研究表明,COS能增加黑质(SN)中的多巴胺能神经元,并能改善帕金森病小鼠模型中的运动障碍。此外,COS 还减少了肠道微生物多样性和粪便中的短链脂肪酸。补充戊酸能增强结肠和黑质神经元的炎症反应,并能逆转 COS - 抑制的多巴胺神经元损伤。自噬参与了 COS 通过戊酸调节炎症的过程。这些结果表明,COS 可减少细菌代谢物--戊酸,从而通过激活自噬作用减轻炎症,最终缓解帕金森病。
期刊介绍:
Journal of Drug Targeting publishes papers and reviews on all aspects of drug delivery and targeting for molecular and macromolecular drugs including the design and characterization of carrier systems (whether colloidal, protein or polymeric) for both vitro and/or in vivo applications of these drugs.
Papers are not restricted to drugs delivered by way of a carrier, but also include studies on molecular and macromolecular drugs that are designed to target specific cellular or extra-cellular molecules. As such the journal publishes results on the activity, delivery and targeting of therapeutic peptides/proteins and nucleic acids including genes/plasmid DNA, gene silencing nucleic acids (e.g. small interfering (si)RNA, antisense oligonucleotides, ribozymes, DNAzymes), as well as aptamers, mononucleotides and monoclonal antibodies and their conjugates. The diagnostic application of targeting technologies as well as targeted delivery of diagnostic and imaging agents also fall within the scope of the journal. In addition, papers are sought on self-regulating systems, systems responsive to their environment and to external stimuli and those that can produce programmed, pulsed and otherwise complex delivery patterns.